These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32591645)

  • 1. Requirement for LIM kinases in acute myeloid leukemia.
    Jensen P; Carlet M; Schlenk RF; Weber A; Kress J; Brunner I; Słabicki M; Grill G; Weisemann S; Cheng YY; Jeremias I; Scholl C; Fröhling S
    Leukemia; 2020 Dec; 34(12):3173-3185. PubMed ID: 32591645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
    Djamai H; Berrou J; Dupont M; Kaci A; Ehlert JE; Weber H; Baruchel A; Paublant F; Prudent R; Gardin C; Dombret H; Braun T
    Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Vulnerabilities in
    Uras IZ; Maurer B; Nebenfuehr S; Zojer M; Valent P; Sexl V
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.
    Uras IZ; Walter GJ; Scheicher R; Bellutti F; Prchal-Murphy M; Tigan AS; Valent P; Heidel FH; Kubicek S; Scholl C; Fröhling S; Sexl V
    Blood; 2016 Jun; 127(23):2890-902. PubMed ID: 27099147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CDK4/6 Inhibitor Palbociclib Synergizes with ATRA to Induce Differentiation in AML.
    Hu L; Li Q; Wang J; Wang H; Ren X; Huang K; Wang Y; Liang X; Pu L; Xiong S; Zhai Z
    Mol Cancer Ther; 2024 Jul; 23(7):961-972. PubMed ID: 38507743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity.
    Yang C; Boyson CA; Di Liberto M; Huang X; Hannah J; Dorn DC; Moore MA; Chen-Kiang S; Zhou P
    Cancer Res; 2015 May; 75(9):1838-45. PubMed ID: 25744718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systems Biology for Drug Target Discovery in Acute Myeloid Leukemia.
    Novikova S; Tolstova T; Kurbatov L; Farafonova T; Tikhonova O; Soloveva N; Rusanov A; Zgoda V
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
    Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S
    J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant expression of NKL homeobox genes HMX2 and HMX3 interferes with cell differentiation in acute myeloid leukemia.
    Nagel S; Pommerenke C; Meyer C; MacLeod RAF; Drexler HG
    PLoS One; 2020; 15(10):e0240120. PubMed ID: 33048949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of CDK4/6 and autophagy synergistically induces apoptosis in t(8;21) acute myeloid leukemia cells.
    Nakatani K; Matsuo H; Harata Y; Higashitani M; Koyama A; Noura M; Nishinaka-Arai Y; Kamikubo Y; Adachi S
    Int J Hematol; 2021 Feb; 113(2):243-253. PubMed ID: 33068248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
    Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
    Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia.
    Lopez S; Voisset E; Tisserand JC; Mosca C; Prebet T; Santamaria D; Dubreuil P; De Sepulveda P
    Oncotarget; 2016 Aug; 7(32):51163-51173. PubMed ID: 27323399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.
    Altman JK; Sassano A; Kaur S; Glaser H; Kroczynska B; Redig AJ; Russo S; Barr S; Platanias LC
    Clin Cancer Res; 2011 Jul; 17(13):4378-88. PubMed ID: 21415215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.
    Hartman AD; Wilson-Weekes A; Suvannasankha A; Burgess GS; Phillips CA; Hincher KJ; Cripe LD; Boswell HS
    Exp Hematol; 2006 Oct; 34(10):1360-76. PubMed ID: 16982329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy.
    Wang L; Shao X; Zhong T; Wu Y; Xu A; Sun X; Gao H; Liu Y; Lan T; Tong Y; Tao X; Du W; Wang W; Chen Y; Li T; Meng X; Deng H; Yang B; He Q; Ying M; Rao Y
    Nat Chem Biol; 2021 May; 17(5):567-575. PubMed ID: 33664520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.
    Keegan K; Li C; Li Z; Ma J; Ragains M; Coberly S; Hollenback D; Eksterowicz J; Liang L; Weidner M; Huard J; Wang X; Alba G; Orf J; Lo MC; Zhao S; Ngo R; Chen A; Liu L; Carlson T; Quéva C; McGee LR; Medina J; Kamb A; Wickramasinghe D; Dai K
    Mol Cancer Ther; 2014 Apr; 13(4):880-9. PubMed ID: 24526162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of Flt3 is a passive event in Hoxa9/Meis1-induced acute myeloid leukemia in mice.
    Staffas A; Arabanian LS; Wei SY; Jansson A; Ståhlman S; Johansson P; Fogelstrand L; Cammenga J; Kuchenbauer F; Palmqvist L
    Oncogene; 2017 Mar; 36(11):1516-1524. PubMed ID: 27617578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
    Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
    Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic and genetic approaches identify Syk as an AML target.
    Hahn CK; Berchuck JE; Ross KN; Kakoza RM; Clauser K; Schinzel AC; Ross L; Galinsky I; Davis TN; Silver SJ; Root DE; Stone RM; DeAngelo DJ; Carroll M; Hahn WC; Carr SA; Golub TR; Kung AL; Stegmaier K
    Cancer Cell; 2009 Oct; 16(4):281-94. PubMed ID: 19800574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
    Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.